Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Total Current Liabilities (2020 - 2025)

Insight Molecular Diagnostics' Total Current Liabilities history spans 6 years, with the latest figure at $7.7 million for Q3 2025.

  • For Q3 2025, Total Current Liabilities fell 15.73% year-over-year to $7.7 million; the TTM value through Sep 2025 reached $7.7 million, down 15.73%, while the annual FY2024 figure was $7.3 million, 1.13% up from the prior year.
  • Total Current Liabilities for Q3 2025 was $7.7 million at Insight Molecular Diagnostics, up from $6.7 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $19.8 million in Q2 2021 and bottomed at $6.7 million in Q2 2025.
  • The 5-year median for Total Current Liabilities is $9.4 million (2023), against an average of $10.4 million.
  • The largest annual shift saw Total Current Liabilities skyrocketed 189.02% in 2021 before it tumbled 45.83% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $14.1 million in 2021, then decreased by 14.26% to $12.1 million in 2022, then plummeted by 40.57% to $7.2 million in 2023, then rose by 1.13% to $7.3 million in 2024, then increased by 5.29% to $7.7 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Total Current Liabilities are $7.7 million (Q3 2025), $6.7 million (Q2 2025), and $9.7 million (Q1 2025).